This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.
The transaction will see Gilead purchase Immunomedics for $88 per share, for a total value of $21bn, and is expected to close during the fourth quarter of the year. ... Immunomedics is also seeking approval in the EU for Trodelvy in the first half of
Regulator wants to see more data on manufacturing. Shares in Immunomedics have gone into steep decline after the FDA rejected its breast cancer drug sacituzumab govitecan. ... Immunomedics’ management also expressed surprise at the rejection,
Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried
The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’ IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’ CEO
Immunomedics shareholders - pointing out that the company has failed to bring any products to market in its 35-year history. ... Now, its would-be partner has decided to duck out of the messy business although it retains a stake in Immunomedics.
An acrimonious battle between the current management of Immunomedics and activist investor group venBio came to a head on Friday after shareholders elected all four of the latter's candidates to ... and punishing Immunomedics for failing to bring any
More from news
Approximately 5 fully matching, plus 4 partially matching documents found.
the first siRNA-based inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) to win approval; and Immunomedics’s sacituzumab govitecan, which is poised become the first antibody-drug conjugate to ... 9. Immunomedic’s sacituzumab govitecan
Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... metastases. The acquisition helps to bolster Seattle's late stage pipeline and comes at a lower price tag than
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... there may be potentially good prospects for Immunomedics to find another partner once the dust has settled. .
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...